A Phase II Study Of The Selective Braf Kinase Inhibitor Gsk2118436 In Subjects With Advanced Non-Small Cell Lung Cancer And Braf Mutations
Posted Date: May 15, 2019
- Investigator: John Morris
- Type of Study: Drug
The purpose of this study is to test the safety of the drug GSK2118436 (dabrafenib) and how well it works. We want to find out what effects, good or bad, it has on people with non-small cell lung cancer. All patients who agree to take part in this study will receive dabrafenib.
To Be Eligible For The Study You Must Have Non-Small Cell Lung Cancer To Be Eligible To Participate.
Cancer, Lung, Braf Mutations, Brf1139287, Nsclc
For More Information:
Uc Cancer Institute